



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. PC10901A	SERIAL NO. 09/779,413
	APPLICANT BANKS, ET AL.	
	FILING DATE FEBRUARY 8, 2001	GROUP NOT YET ASSIGNED

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE


FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
		0	8	8	2	7	1	9	12/98	EPO				X
		9	8	5	7	9	3	8	06/98	PCT				X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

1.		H. Arai, et al.; Cloning and expression of a cDNA encoding an Endothelin receptor; Nature; Vol. 348, pp. 730-732 (1990).
2.		A. Tahara, et al.; Circulating Immunoreactive Endothelin in Patients Undergoing Percutaneous Transluminal Coronary Angioplasty; Metab. Clin. Exp.; Vol. 40, pp. 1235-1237 (1991).
3.		S. Douglas, et al.; Endothelin-1 Promotes Neointima Formation After Balloon Angioplasty in the Rat; J. of Cardiovascular Pharm.; 22 (Suppl. 8), 371-373 (1993).
4.		S. Douglas, et al.; A Role for Endogenous Endothelin-1 in Neointimal Formation After Rat Carotid Artery Balloon Angioplasty; Circ. Res.; Vol. 75, pp. 190-197 (1994).
5.		H. Krum, et al.; The effect of an Endothelin-Receptor Antagonist, Bosentan, on Blood Pressure in Patients with Essential Hypertension; New England J. Med.; Vol. 338, pp. 784-790 (1998).
6.		F. E. Strachan, et al.; Systemic Blockade of the Endothelin-B Receptor Increases Peripheral Vascular Resistance in Healthy Men; Hypertension; Vol. 33, p. 581-585 (1999).
7.		Y. Saita, et al.; Mitogenic Activity of Endothelin on Human Cultured Prostatic Smooth Muscle Cells; Eur. J. Pharmacol.; Vol. 349, pp. 123-128 (1988).
8.		R. K. Nikolov, et al.; Cerebrovascular and CNS Effects of Endothelins - Target for Pharmacological Modification; Drugs of Today; Vol. 28(5), 303-310 (1992).
9.		A. E. Benamou, et al.; Variations in Systemic and Pulmonary Endothelin-1 in Horses with Recurrent Airway Obstruction (Heaves); Pulm. Pharm. Ther. Vol. 11, pp. 231-235 (1998).

EXPRESS MAIL NO. EL639818392US



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC10901A	SERIAL NO. 09/779,413
		APPLICANT BANKS, ET AL.	
		FILING DATE FEBRUARY 8, 2001	GROUP NOT YET ASSIGNED
10.		A. E. Redington, et al.; Endothelin in Bronchoalveolar Lavage Fluid and Its Relation to Airflow Obstruction in Asthma; Am. J. Resp. Crit. Care Med.; Vol. 151, pp. 1034-1039 (1995).	
11.		K. Tomita, et al.; Molecular analysis of acute renal failure; Med. Philos.; Vol. 13(1), pp. 64-66 91994).	
12.		F. Stockenhuber, et al.; Plasma levels of Endothelin in Chronic Renal Failure and after renal Transplantation: Impact on hypertension and Cyclosporin A-associated Nephrotoxicity; Clinical Science; Vol. 82, pp. 225-258 (1992).	
13.		M. Yasuda, et al.; Circulating Immunoreactive Endothelin in Ischemic heart Disease; Am. Heart Journal; Vol. 119(4), pp. 801-806 (1990).	
14.		J. T. Stewart, et al.; Plasma Endothelin in Coronary Venous Blood from Patients with Either Stable or Unstable Angina; Br. Heart Journal; Vol. 66, pp. 7-9 (1991).	
15.		D. J. Stewart, et al.; Increased Plasma Endothelin-1 in Pulmonary Hypertension: Marker or Mediator of Disease; Ann. Internal Medicine; Vol. 114, pp. 464-469 (1991).	
16.		R. J. Rodeheffer, et al.; Circulating Plasma Endothelin Correlates with the Severity of Congestive Heart Failure in Humans; Am. Journal of Hypertension; Vol. 4:9A (1991).	
17.		B. A. Clark, et al.; Plasma Endothelin Levels in Preeclampsia: Elevation and Correlation with Uric Acid Levels and Renal Impairment; Am. Journal Obstet. Gynecol.; Vol. 166, pp. 962-969 (1992).	
18.		A. Collier, et al.; Plasma Endothelinlike Immunoreactivity Levels in IDDM Patients with Microalbuminuria; Diabetes Care; Vol. 15(8), pp. 1038-1040 (1992).	
19.		S. H. Murch, et al.; High Endothelin-1 Immunoreactivity in Crohn's Disease and Ulcerative Colitis; Ann. Internal Medicine; Vol. 339, pp. 381-385 (1992).	
20.		A. Lerman, et al.; Circulating and Tissue Endothelin Immunoreactivity in Advanced Atherosclerosis; The New England J. of Medicine; Vol. 325(14), pp. 997-1001 (1991).	
21.		W. J. Jusko, et al.; Plasma and Tissue Protein binding of Drugs in Pharmacokinetics; Drug Metabolism Reviews; Vol. 5(1), pp. 43-140 (1976).	
22.		D. K. Detweiler, et al.; The Prevalence and Types of Cardiovascular Disease in Dogs; Ann. N.Y.Acad. Sci. 481-516.	
23.		R. R. Pensinger; Comparative Aspects of Congestive Heart Failure in Dogs; pp. 335-345 (1986).	
24.		A. Tidholm, et al.; Survival and Prognostic Factors in 189 dogs with Dilated Cardiomyopathy; Journal Am. An. Hosp. Assoc.; Vol. 33, pp. 364-368.	
25.		S. J. Ettinger, et al.; Effects of Enalapril Maleate on Survival of Dogs with Naturally Acquired Heart Failure; JAVMA; Vol. 213 (11), pp. 1573-1577 (1998).	
26.		W. L. Miller, et al.; Integrated Cardiac, Renal, and Endocrine Actions of Endothelin; J. Clin. Invest.; Vol. 83, p. 317-320 (1989).	
27.		R. Pacher, et al.; Prognostic Impact of Big Endothelin-1 Plasma Concentrations Compared With Invasive hemodynamic Evaluation in Severe Heart Failure; JACC; Vol. 27(3); pp. 633-641 (1996).	
28.		G. W. Moe, et al.; Beneficial Effects of long-term Selective Endothelin Type A Receptor Blockade in Canine Experimental Heart Failure; Cardiovascular Research; Vol. 39, pp. 571-579 (1998).	
29.		H. N. Coleman, et al.; Congestive Heart Failure Following Chronic Tachycardia; American Heart Journal; Vol. 81(6), pp. 790-799 (1971).	
30.		G. Hasenfuss; Animal Models of Human Cardiovascular Disease, Heart Failure and Hypertrophy; Cardiovascular Research; Vol. 39, pp. 60-76 (1998).	

Handwritten signature and date: 2/11/02



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC10901A	SERIAL NO. 09/779,413
		APPLICANT BANKS, ET AL.	
		FILING DATE FEBRUARY 8, 2001	GROUP NOT YET ASSIGNED
31.		N. Sato, et al.; Mechanisms of Desensitization to a PDE inhibitor (Milrinone) in Conscious Dogs with Heart Failure; Am. Journal Physiol.; Vol. 276, pp. 1699-1705 (1999).	
32.		Sanagi, et al.; Pharmacological profile of YM-598, a novel non-peptide ETA receptor Selective Antagonist; XIIIth International Congress of Pharmacology, Munich, Germany 26-31 (1998).	
EXAMINER DATE CONSIDERED 2/11/02			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE